Table 3.

Summary of specific tumor incidence in BALB/c mice treated neonatally and sacrificed at 20 months of age.

	Incidence of tumor type
Neonatal treatment (μg/pup/day)	ML	H	BA	C	CV	OG	MG	Ota	TNTb	No.c
Oil	1	0	0	0	0	0	0	0	1	33
E2 (5)	0	0	1	2	16**	1	1	0	18**	37
E2 (2.5)/OH-PCB-30 (100)	0	0	0	0	9**	3*	0	1	11*	19
OH-PCB-30 (200)	0	0	0	1	10**	3	0	0	12*	22
OH-PCB-30 (20)	0	0	3	0	2	0	5	0	9*	33
OH-PCB-61 (400)	0	2	0	0	5*	0	1	2	11*	24
OH-PCB-61 (40)	2	1	0	0	4*	3	4*	2	15*	30
OH-PCB-30/61 (100 + 100)d	2	0	1	0	8*	2	0	2	13*	21
OH-PCB-30/61 (10 + 10)d	0	0	0	0	3	1	3	1	8*	36

Abbreviations: BA, bronchoalveolar; C, cholangiocarcinoma of the gallbladder; CV, cervicovaginal tract carcinoma; H, hemangiosarcoma; OG, ovarian granulosa cell tumor; MG, mammary gland carcinoma; ML, malignant lymphoma; OG, ovarian granulosa cell tumor; Ot, other types of tumors not listed; TNT, total number of tumors found in that treatment group. Pups were treated as described in “Materials and Methods.”

^aTumor type occurred in no more than one animal per group.

^bSome mice had more than one type of tumor.

^cNumber of mice diagnosed by H&E staining.

^dEqual concentrations of OH-PCB-30 and OH-PCB-61 were used as a mixture.

*p < 0.05 versus sesame oil control (Fisher exact test).

**p < 0.01 versus sesame oil control (Fisher exact test).